Insider Buying: Liquidia (NASDAQ:LQDA) Director Purchases 5,300 Shares of Stock

Liquidia Corporation (NASDAQ:LQDAGet Free Report) Director Caligan Partners Lp acquired 5,300 shares of the company’s stock in a transaction dated Tuesday, May 19th. The stock was purchased at an average cost of $59.98 per share, for a total transaction of $317,894.00. Following the purchase, the director directly owned 8,138,951 shares in the company, valued at approximately $488,174,280.98. This represents a 0.07% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through this link.

Liquidia Price Performance

Shares of LQDA traded up $1.79 during midday trading on Wednesday, reaching $61.77. The stock had a trading volume of 1,754,852 shares, compared to its average volume of 1,557,702. Liquidia Corporation has a 52 week low of $11.85 and a 52 week high of $62.17. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The firm’s 50 day moving average price is $41.15 and its 200-day moving average price is $36.81. The company has a market capitalization of $5.49 billion, a P/E ratio of 441.25 and a beta of 0.41.

Liquidia (NASDAQ:LQDAGet Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.11. The company had revenue of $132.87 million during the quarter, compared to analyst estimates of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The company’s revenue for the quarter was up 4187.1% on a year-over-year basis. On average, analysts forecast that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on LQDA. Wall Street Zen upgraded shares of Liquidia from a “buy” rating to a “strong-buy” rating in a report on Saturday. Lifesci Capital upgraded shares of Liquidia to a “strong-buy” rating in a report on Thursday, March 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a report on Tuesday, April 21st. Raymond James Financial restated a “strong-buy” rating on shares of Liquidia in a report on Thursday, March 5th. Finally, Zacks Research upgraded shares of Liquidia from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 5th. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Liquidia currently has a consensus rating of “Moderate Buy” and an average target price of $49.33.

Get Our Latest Research Report on LQDA

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in LQDA. Farallon Capital Management LLC boosted its holdings in shares of Liquidia by 102.1% in the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after buying an additional 4,326,876 shares during the period. TCG Crossover Management LLC acquired a new position in shares of Liquidia in the third quarter worth about $38,887,000. Caprock Group LLC acquired a new stake in shares of Liquidia during the third quarter worth approximately $37,114,000. MPM Bioimpact LLC boosted its holdings in shares of Liquidia by 600.4% during the fourth quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock worth $48,316,000 after purchasing an additional 1,200,869 shares during the period. Finally, Voloridge Investment Management LLC acquired a new stake in shares of Liquidia during the third quarter worth approximately $12,571,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

About Liquidia

(Get Free Report)

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).

Read More

Insider Buying and Selling by Quarter for Liquidia (NASDAQ:LQDA)

Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.